AgeX Therapeutics, Inc.
AGE
Price:
$11.1
Market Cap:
$27.76M
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation...[Read more]
Industry
Biotechnology
IPO Date
2018-11-29
Stock Exchange
AMEX
Ticker
AGE
The ROE as of September 2024 (TTM) for AgeX Therapeutics, Inc. (AGE) is 172.71%
According to AgeX Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is 172.71%. This represents a change of 268.52% compared to the average of 46.87% of the last 4 quarters.
AgeX Therapeutics, Inc. (AGE) Historical ROE (quarterly & annually)
How has AGE ROE performed in the past?
The mean historical ROE of AgeX Therapeutics, Inc. over the last ten years is -93.89%. The current 172.71% ROE has changed -283.96% with respect to the historical average. Over the past ten years (40 quarters), AGE's ROE was at its highest in in the March 2020 quarter at 431.26%. The ROE was at its lowest in in the December 2019 quarter at -122.23%.
Average
-93.89%
Median
-90.38%
Minimum
-558.34%
Maximum
214.54%
AgeX Therapeutics, Inc. (AGE) ROE by Quarter and Year
Discovering the peaks and valleys of AgeX Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 454.25%
Maximum Annual ROE = 214.54%
Minimum Annual Increase = -536.46%
Minimum Annual ROE = -558.34%
| Year | ROE | Change |
|---|---|---|
| 2023 | -270.67% | -536.46% |
| 2022 | 62.01% | -28.20% |
| 2021 | 86.38% | -59.74% |
| 2020 | 214.54% | -138.43% |
| 2019 | -558.34% | 454.25% |
| 2018 | -100.74% | 11.46% |
AgeX Therapeutics, Inc. (AGE) Average ROE
How has AGE ROE performed in the past?
The current ROE of AgeX Therapeutics, Inc. (AGE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-40.76%
5-year avg
-93.22%
10-year avg
-93.89%
AgeX Therapeutics, Inc. (AGE) ROE vs. Peers
How is AGE’s ROE compared to its peers?
AgeX Therapeutics, Inc.’s ROE is greater than MAIA Biotechnology, Inc. (-18051.81%), greater than Larimar Therapeutics, Inc. (-37.84%), greater than Graphite Bio, Inc. (-57.96%), greater than Lyra Therapeutics, Inc. (-143.74%), greater than Lineage Cell Therapeutics, Inc. (-35.54%), greater than Cadrenal Therapeutics, Inc. Common Stock (-93.71%), greater than ImmuCell Corporation (-16.35%), greater than Oxford Nanopore Technologies plc (-43.29%), less than Praxis Precision Medicines, Inc. (0%), greater than Foghorn Therapeutics Inc. (-61.47%), less than Synaptogenix, Inc. (140.34%), greater than Invivyd, Inc. (-7.32%), greater than Biohaven Pharmaceutical Holding Company Ltd. (-109.72%), greater than Immunome, Inc. (-212.83%), greater than Inhibrx, Inc. (-157.86%), less than Icosavax, Inc. (1.62%), greater than null (-41.24%),
| Company | ROE | Market cap |
|---|---|---|
| -18051.81% | $66.94M | |
| -37.84% | $437.08M | |
| -57.96% | $185.19M | |
| -143.74% | $17.92M | |
| -35.54% | $166.18M | |
| -93.71% | $12.79M | |
| -16.35% | $28.20M | |
| -43.29% | $1.99B | |
| 0% | $1.05B | |
| -61.47% | $528.94M | |
| 140.34% | $4.26M | |
| -7.32% | $139.75M | |
| -109.72% | $3.72B | |
| -212.83% | $930.84M | |
| -157.86% | $245.95M | |
| 1.62% | $769.04M | |
| -41.24% | $0 |
Build a custom stock screener for AgeX Therapeutics, Inc. (AGE) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like AgeX Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
AgeX Therapeutics, Inc. (AGE) and other stocks custom spreadsheet templates
The easiest way to analyze a company like AgeX Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is AgeX Therapeutics, Inc.'s ROE?
How is the ROE calculated for AgeX Therapeutics, Inc. (AGE)?
What is the highest ROE for AgeX Therapeutics, Inc. (AGE)?
What is the 3-year average ROE for AgeX Therapeutics, Inc. (AGE)?
What is the 5-year average ROE for AgeX Therapeutics, Inc. (AGE)?
How does the current ROE for AgeX Therapeutics, Inc. (AGE) compare to its historical average?